Email

I@gatesfoundation.org> Ce: Robert Nabors| (@gatesfoundation.org>; Christa Bowles I@gatesfoundation.org>; Conrad, Patricia (NIH/NIAID) [E] I@niaid.nih.gov>; Jennifer Weisman I@gatesfoundation.org>; Mascola, John (NIH/VRC) [E] I@mail.nih.gov> Subject: RE: Following up Thanks, Trevor. I am copying John Mascola on this e-mail. He can fill you in on what we are doing at the VRC. Best regards, Tony From: Trevor Mundel EEE © catesfoundation.org> Sent: Saturday, January 16, 2021 9:59 AM >; Conrad, I nifer Weisman > To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov> Cc: Robert Nabors @gatesfoundation.org>; Christa Bowles @gatesfoundation.org>; Conrad, Patricia (NIH/NIAID) [E] < @niaid.nih.gov>; Jennifer Weisman @gatesfoundation.org> Subject: Following up Hi Tony, Thanks for connecting with Bill and myself on Wednesday - there were a couple of areas we had discussed for potential follow on collaboration. First was any work you are doing through the VRC to adapt the Spike/other antigens in response to the new variants (I think Barney's work that was picked up by Novavax and some of the other companies will be very important). Let me know if there is anything we can help out with in this work. I'll also be in touch with Francis around the sequencing in the US and in Africa - we've had a lot of help here from Illumina and other companies. Warm regards, Trevor Trevor Mundel, MD, PhD President, Global Health Program E @gatesfoundation.org Christa Bowles Executive Assistant Global Health Office of the President E @gatesfoundation.org Dugan, Ker ff a csony, voc, 00 mse Schorr, Timo I@darpa.mil]; van Opstal, Edward (contr-bto) )darpa.mil]; Samira (contr-bto)I arpa. ; Martin, Charles (contr-bto)I larpa.mil Ripp, Angela (col Subject: I BMGF Briefs Received: Mon 5/2/2022 12:50:59 PM PREEMPT Overview for Bioinnovation Accelerator BMGF-Distro A_JORDAN.pptx 05032022 FoF DISTAR.pptx 2022-05 BMGF INTERCEPT Briefing.pptx ReVector -BMGF wo VT.pptx BMGF Accelerator Intro Overview Pre-read May 2022. pdf smime.p7s Hi Kerri and Kristen, Here are the briefings for tomorrow's BMGF meeting if you'd like to take a look at them prior. Tim will be in the room loggedin/projecting the decks in 11-300 for the briefers and Chuck will escort them up to the room. We are still on schedule for the following agenda: 3:30-4:00pm BMGF Overview (Kerri, Kirsten, Cathy dialing-in) 4:00-4:05pm Briefers arrive to 11-300/Intros (Clare, Tiffany, Linda) 4:05-4:15pm INTERCEPT Overview -- Dr. Clare Rowland 4:15-4:25pm PREEMPT Overview -- Dr. Kristen Jordan 4:25-4:35pm Friend or Foe Overview -- Dr. Tiffany Prest 4:35-4:45pm ReVector Overview -- Dr. Linda Chrisey 4:45-5:00pm Q&A/Wrap-up Angela Angela Ripp Biological Technologies Office Defense Advanced Research Projects Agency Contractor, Strategic Analysis ME © d2r0.ri PREventing EMerging Pathogenic Threats PREEMPT Kristen Jordan, Ph.D. Biological Technologies Office Bicinnovation Accelerator Bil and Melinda Gates Foundation May 3, 2022 JAR COARPA) Program Overview DoD Problem: DOD Problem: Military personnel are regularly deployed to areas at high risk of acquisition of emerging infectious diseases in humans originate in animais and are I Fact: About 60-80% of infectious diseases transmitted by animals or insects Intermediate Reservoir ("44 Vector Global! Virome Project: There are on the order of 600-800K unknown viruses among mammals and birds that have the potentiat to make a zoonotic leap (Science, 2018) Reservoirs > Vision: Significantly reduce viral threat surprise by preemptively blocking new outbreaks via targeting viruses in animals before they emerge in humans COARPA) PREEMPT Technical Areas DARPA's Approach: Preemptively. d/eck spillover of viral pathogens by targeting and-intervening-at-the-animal-/-insect-reservoir TAL: Develop new tools to predict virus jump into humans Analysis Validation ».. Animal models Jump Risk Model »